RxDoctor Payments DataLook up a doctor →

Kenneth Dawes, MD

Dermatology · Indianapolis, INNPI 1497758627

Payments from drug & device makers

$2,214,261in general payments, 2019–2025

Across 1,790 payments — averaging $1237.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$336K
  • Incyte Corporation$313K
  • Janssen Research & Development, LLC$305K
  • Pfizer$180K
  • Aclaris Therapeutics, Inc.$178K
  • Sun Pharmaceutical Industries Inc.$172K
  • plus $730K from 43 others
$87,634in research payments, 2019–2025

Across 19 payments — averaging $4612.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$84K
  • Mayne Pharma Commercial LLC$4K
  • Eli Lilly$629

What the payments were for

  • Consulting fees$2,1504%
  • Speaking & faculty fees$33,02565%
  • Travel & lodging$1,1782%
  • Food & beverage$14,08528%
  • Education$3941%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,214,261 in reported general payments places this provider in the 95th percentile of 202 dermatology providers in Indiana.

See all dermatology providers in Indiana

Medicare billing

Part B allowed, 2024
$1,310,467
Medicare patients
2,756
Services billed
15,518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab35$271,654
Dupixent PenDupilumab73$270,573
Skyrizi PenRisankizumab-Rzaa13$267,195
Taltz AutoinjectorIxekizumab28$246,963
Humira(Cf) PenAdalimumab21$191,418
OtezlaApremilast34$161,521
SotyktuDeucravacitinib14$94,268
Dupixent SyringeDupilumab22$82,103
OdomzoSonidegib Phosphate11$81,898
SiliqBrodalumab14$73,686
Fluocinonide392$15,786
Fluorouracil126$10,158
Clobetasol Propionate216$8,966
Ketoconazole407$7,034
Metronidazole87$6,317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$2,886$161,52134 claims
E.r. Squibb & Sons, L.L.C.Sotyktu$119,276$94,26814 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCSiliq$212$73,68614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 202 dermatology providers in Indiana.

Other dermatology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →